SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: Andrew Q. Viet who wrote (206)4/10/1998 5:22:00 PM
From: shortlong2  Read Replies (2) | Respond to of 712
 
Part of Merck <MRK> news release.
"The FDA Panel declined to vote on backing Aggrastat's use during angioplasty to prevent heart attack, repeat procedures and abrupt artery closure after reviewing results of a separate study called RESTORE"............. "The FDA told COR Therapeutics Inc. last week that its similar glycoprotein IIb/IIIa blocker, Integrilin, will soon be approved to use during angioplasty AND for unstable angina."


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News